In a pilot project, Optima Pharma and Charité – Universitätsmedizin Berlin are developing a production platform for the automatic manufacturing and filling of cell and gene therapeutics. These new types of medicine are paving the way for personalized medicine and are considered a promising new therapy possibility for hereditary and metabolic diseases, neurodegenerative disorders, and cancer. These medications depend on the patient’s cells and are still produced manually, for each individual pati...